

ABOUT THE AUTHOR



Seth R. Shaffer, MD, MS

Dr. Shaffer is a gastroenterologist at Health Sciences Centre in Winnipeg, Manitoba, and an Assistant Professor of Medicine at the University of Manitoba. He completed medical school at the University of Manitoba and then went to Queen's University for his Internal Medicine residency. He returned to the University of Manitoba for a fellowship in gastroenterology. He then completed an advanced fellowship in Inflammatory Bowel Disease at the University of Chicago, and a Master's degree in Public Health Sciences, with an interest in health economics. Dr. Shaffer is a member of the University of Manitoba IBD Clinical and Research Centre. His research focuses on understanding the causes and clinical management of persons with IBD, and the economic impact of caring for people with IBD.

Affiliations: Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba

Inflammatory Bowel Disease in the Elderly

Seth R. Shaffer, MD, MS

Introduction

The incidence of inflammatory bowel disease (IBD) among the elderly in Canada has increased from 1 out of 160 seniors in 2018, to 1 out of 88 seniors in 2023, representing 1.14% of the senior population.¹ It is thought that more than one-third of all IBD patients will be over 60 years of age in the next decade.² The prevalence is expected to increase due to a combination of new diagnoses as well as the aging of younger people already living with IBD.

Elderly persons with IBD face unique challenges that younger people with IBD often do not, such as co-existing comorbidities, frailty, polypharmacy, and an increased risk of infections and cancer. While the therapeutic management of elderly persons with IBD is similar to that of younger people with IBD, it requires careful consideration of many different factors, and special attention is needed when weighing the risks and benefits of medical therapy.

Clinical Presentation

Elderly-onset Crohn's disease (CD) is more frequent in females, while elderly-onset ulcerative colitis (UC) is more common in males.^{3,4}

Elderly persons with IBD can present with different symptoms compared to younger people with IBD. In UC, weight loss is more commonly reported, while rectal bleeding and abdominal pain are less commonly reported.³ Left sided disease is the most common presentation. Additionally, the cumulative 5-year risk of surgery is 7.8%, which is similar to that of adults with IBD.⁵ Compared with younger individuals with CD, elderly people are more likely to have isolated colonic disease, as well as fibrostenosis, while penetrating or perianal disease is rare.^{5,6} Rectal bleeding, diarrhea, abdominal pain, and weight loss are all less common.³ The cumulative 5-year risk of surgery for those over the age of 60 with CD is 22.6%.⁵ Rates of primary sclerosing cholangitis and dermatologic manifestations of IBD are similar between elderly persons and younger adults,

with elderly persons having higher rates of ocular manifestations of IBD, and lower rates of arthritis.⁷

In addition, the risk of post-operative mortality is higher in elderly persons with IBD compared to younger people, with rates of 6.1% versus 0.7% in UC and 4.2% versus 0.3% in CD. The risk of non-fatal post-operative complications is similarly higher for elderly people with both CD and UC.⁸

It is important to consider other causes of intestinal inflammation in elderly people, as the differential diagnosis can be broad. This includes conditions such as infectious colitis, microscopic colitis, ischemic colitis, segmental colitis associated with diverticulosis, radiation colitis, and malignancy.⁹ For this reason, elderly people can often be misdiagnosed,¹⁰ which can lead to delays in receiving appropriate treatment.

Comorbidities in the Elderly

Persons with IBD are at an increased risk of developing osteoporosis, a risk that cannot be solely attributed to corticosteroid use.¹¹ A population-based study in Manitoba showed that people over the age of 65 years with IBD have an increased risk of cerebrovascular disease (hazard ratio [HR] 1.19, 95% confidence interval [CI] 1.01–1.40), cardiac disease (HR 1.24, 95% CI 1.07–1.43), peripheral vascular disease (HR 1.36, 95% CI 1.14–1.62), cancer (HR 1.21, 95% CI 1.04–1.40), and other comorbidities.¹² A large US study assessing a nationwide database found that persons with IBD over the age of 65 are more likely to be hospitalized with serious infections and cardiovascular complications compared to individuals aged 40–64 and those younger than 40.¹³

Disease Related Complications

Ananthakrishnan et al. showed that older persons with IBD (65 years or older) who are hospitalized for their condition have an increased mortality compared to those with IBD aged 19–64 years (odds ratio [OR] 3.91, 95% CI 2.50–6.11). This mortality risk is even higher when compared to just those aged 19–35 years (OR 17.42, 95% CI 8.92–33.99).¹⁴ A large US cohort study found that the risk of herpes zoster was higher in those with IBD treated with 5-ASA only compared to persons without IBD (adjusted HR [aHR] 1.72, 95% CI 1.51–1.96). Within the IBD cohort, age was identified as a risk factor for

becoming infected.¹⁵ A retrospective study that included¹³ hospitals in Hong Kong showed that elderly-onset persons with IBD have a higher risk of developing herpes zoster (OR 2.42, 95% CI 1.22–4.80), cytomegalovirus colitis (OR 3.07, 95% CI 1.92–4.89), all-cancer development (OR 2.97, 95% CI 1.84–4.79), and IBD-related hospitalizations (OR 1.14, 95% CI 1.09–1.20) compared with those with adult-onset IBD.⁶

Access to Care

It has been reported that technology literacy decreases with age,¹⁶ making it difficult for elderly persons with IBD to access their gastroenterologist, particularly as more health care providers have been incorporating virtual care into their practices since the COVID-19 pandemic. Additionally, research has shown that elderly persons with IBD who are treated by a gastroenterologist, or are part of a network with more gastroenterologists, experience better outcomes. These patients are more likely to be prescribed a biologic or immunomodulator compared with those who are not treated by a gastroenterologist.¹⁷

Frailty

Frailty describes a state where one has a decreased physiologic reserve in response to a stressor, which is often not related to chronologic age, but more to biologic age. Although frailty can theoretically occur at any age, it is more common in the elderly. Frailty has been shown to be related to low-grade inflammation with elevated levels of c-reactive protein (CRP), tumor-necrosis factor-alpha (TNF-alpha), and interleukin-6.¹⁸ It has been shown that fecal calprotectin levels can be elevated in various diseases such as ischemic colitis, neoplasm, and even diverticulitis, as well as with certain therapies such as non-steroidal anti-inflammatory drugs and proton pump inhibitors.¹⁹ Since these are more common in the elderly, biomarkers such as CRP and fecal calprotectin may be less specific for disease activity in the elderly with IBD. Studies reveal that frailty is present in 5–33% of persons with IBD,^{20–22} and is more common in older persons with IBD compared to those without IBD.²³ The presence of frailty in persons with IBD is associated with an increase in adverse outcomes, including prolonged hospitalization, readmission to hospital

for IBD, and mortality.^{22,24} One study also showed that the presence of pre-treatment frailty was associated with an increased risk of infections in those receiving immunomodulators and anti-TNF therapy.²⁵

Polypharmacy

Polypharmacy, often defined as the use of 5 or more medications, is a concern in the elderly, as it can lead to non-adherence with IBD therapies. In people 65 years or older, polypharmacy has been associated with adverse outcomes including drug interactions, falls, urinary incontinence, and cognitive decline.²⁶ In addition, it poses a risk of flaring in those with IBD (OR 4.0, 95% CI 1.66–1.92).²⁷ A study of senior persons with IBD showed that each individual had on average 9 prescribed medications, and 40% of them had a potential drug interaction involving one of their IBD therapies.²⁸ A retrospective study of persons with IBD aged 60 years or older showed that almost three-quarters of the patients experienced polypharmacy. Severe polypharmacy, defined as taking 10 or more medications, was associated with an increased risk of hospitalization (aHR 2.16, 95% CI 1.37–3.43).²⁹

Deficits

Geriatric deficits are more common in elderly persons with IBD, and those with active disease are more likely to have deficits compared to those without.³⁰ The same study also found that elderly persons who were diagnosed with IBD at age 60 or later are more likely to experience cognitive impairment, reduced handgrip strength, and slower gait speed. These deficits are also associated with a lower health-related quality of life.

Treatment and Safety

While therapeutic efficacy for elderly persons with IBD is mostly similar to that of younger patients, there are potential complicating factors to consider. These include increased risks of infection and malignancy, and the potential for drug-drug interactions.

Corticosteroids remain effective for induction therapy and for rapidly improving symptoms in persons with IBD. A systematic review and meta-analysis showed that the use of corticosteroids in persons with IBD over 60 years

of age is similar to their use in those younger than age 60, however, the study also showed that the use of immunomodulators and biologics is lower among elderly persons with IBD.⁵

Oral 5-ASA therapies are an effective and safe therapy for inducing and maintaining remission for mild-to-moderate UC, and despite its lack of evidence for their use in CD, they remain widely used.³ Thiopurines continue to be effective treatments for both UC and CD. A cohort study following elderly persons with IBD has shown that one-fifth of patients were exposed to thiopurines within 5 years of their diagnosis.³¹ Thiopurine use, however, can increase the risk of infections,³² non-melanoma skin cancers in persons over 65,³³ and lymphoproliferative disorders in those over 50.³⁴ In elderly patients with IBD who start a thiopurine over 60, they are at an increased risk of adverse events including infections, neoplasms, and hematologic abnormalities compared to those who are less than 50 who start a thiopurine.³⁵

Anti-TNF therapies remain an important option for elderly persons with IBD, especially for those who are hospitalized, steroid dependent, or steroid refractory. However, the evidence for anti-TNF efficacy in older people with IBD is conflicting. Some studies show that elderly persons have a lower persistence with anti-TNF therapy and are more likely to experience treatment failure.^{36,37} Alternatively, analyses from randomized trials show no difference between the older cohort (60 years old and older) compared with the younger cohort (younger than 60) in terms of inducing and maintaining remission.³⁸ A pooled analysis from randomized trials assessing anti-TNF found an increased risk of adverse events in people aged over 60 years with UC. However, age was a more significant predictor of these adverse events than the anti-TNF therapy.³⁸ Persons over 60 with immune-mediated inflammatory diseases who were on biologics had an increased risk of infection compared to both older people not on biologics and younger persons on biologics.³⁹ One study showed that combination therapy involving anti-TNF and a thiopurine in persons over 60 was associated with an increased risk of herpes zoster infection.¹⁵ However, another study observed no difference in infection risk for those over 60 years on combination therapy compared to those receiving conventional treatment.⁴⁰

Vedolizumab, a gut-specific monoclonal antibody, is effective in the elderly, with an efficacy comparable to younger persons.^{41,42}

In a retrospective cohort of persons over 60 assessing vedolizumab and anti-TNF therapy, vedolizumab was discontinued less frequently (25.9% versus 51.9%), and had higher endoscopic remission rates (65.7% versus 45.2%).⁴³ Vedolizumab is effective in the elderly, and is equally as effective and safe as ustekinumab in elderly persons with CD.^{44,45} A retrospective study in Italy showed a higher persistence on vedolizumab in non-elderly persons with UC compared with people over 65 years-old, but this was not seen with CD, although they did not control for prior anti-TNF exposure.⁴⁶ Vedolizumab has a lower risk of infectious complications and is considered safe for elderly patients.⁴⁷

Ustekinumab, an anti-IL12/23 antibody, has comparable effectiveness across all age groups.⁴⁸ One study showed that rates of mucosal healing were similar in the older (65 years and older) and younger (<65 years) cohorts.⁴⁹ It is also considered safe for elderly patients, with no increased risk of infectious complications.⁵⁰

Newer anti-IL23 antibody treatments are also considered equally effective and safe among all age groups, including elderly patients, with no increased risk of infections or malignancy.^{51,52}

Advanced oral therapies, including Janus kinase inhibitors (JAKi) (tofacitinib and upadacitinib) and oral S1P receptor modulators (ozanimod and etrasimod), have emerged as therapeutic options in recent years. Clinical trial data assessing etrasimod in UC have shown that outcomes are similar across all age groups, including those over 60.⁵³ Additionally, safety outcomes are similar across all age groups with no increased risk of infection.^{53,54} Tofacitinib has been shown to be effective in treating UC across all age groups. However, age was a significant predictor for herpes zoster infection, malignancies excluding non-melanoma skin cancers (NMSC), and NMSC.⁵⁵ Small studies have shown upadacitinib to be effective in older people with UC,⁵⁶ and it is also indicated in the treatment of CD. The safety profile of upadacitinib in the elderly is thought to be comparable to younger people⁴⁹, though there is an increased risk of herpes zoster infection with JAKi treatment and this risk increases with age.⁵⁷ Hence, it is imperative that persons with IBD be vaccinated against herpes zoster regardless of their therapy, but especially if they are starting treatment with a JAKi.

Conclusion

The prevalence of IBD in elderly persons is only increasing, presenting unique challenges for their management. When treating elderly persons with IBD, one must be cognizant of age, comorbidities, polypharmacy, frailty, and access to care. Anti-TNF therapies are potentially associated with an increased risk of infection, therefore, biologics with improved side effect profiles should be considered when appropriate. Owing to the complex medical needs of elderly persons with IBD, a multidisciplinary approach is essential to provide comprehensive care.

Correspondence

Seth R. Shaffer, MD, MS

Email: seth.shaffer@umanitoba.ca

Financial Disclosures

S.S.: None declared.

References

1. Shaffer SR, Kuenzig ME, Windsor JW, Bitton A, Jones JL, Lee K, et al. The 2023 Impact of inflammatory bowel disease in Canada: special populations-IBD in seniors. *J Can Assoc Gastroenterol*. 2023;6(Suppl 2):S45-s54. doi:10.1093/jcag/gwad013
2. Axenfeld E, Katz S, Faye AS. Management considerations for the older adult with inflammatory bowel disease. *Gastroenterol Hepatol (N Y)*. 2023;19(10):592-599.
3. Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberrenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut*. 2014;63(3):423-432. doi:10.1136/gutjnl-2012-303864
4. Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. *Gastroenterology*. 2019;156(5):1345-1353.e1344. doi:10.1053/j.gastro.2019.01.002
5. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol*. 2020;18(11):2437-2447.e2436. doi:10.1016/j.cgh.2020.02.048

6. Mak JWY, Lok Tung Ho C, Wong K, Cheng TY, Yip TCF, Leung WK, et al. Epidemiology and natural history of elderly-onset inflammatory bowel disease: results from a territory-wide Hong Kong IBD Registry. *J Crohns Colitis*. 2021;15(3):401-408. doi:10.1093/ecco-jcc/jjaa181
7. Everhov AH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Soderling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. *Gastroenterology*. 2018;154(3):518-28 e15. doi:10.1053/j.gastro.2017.10.034
8. Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality and complications among elderly patients with inflammatory bowel diseases: an analysis of the national surgical quality improvement program cohort. *Clin Gastroenterol Hepatol*. 2016;14(9):1274-1281. doi:10.1016/j.cgh.2015.11.012
9. Schofield JB, Haboubi N. Histopathological mimics of inflammatory bowel disease. *Inflamm Bowel Dis*. 2020;26(7):994-1009. doi:10.1093/ibd/izz232
10. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogeand RA. Crohn's disease in the elderly: a comparison with young adults. *J Clin Gastroenterol*. 1998;27(2):129-133. doi:10.1097/00004836-199809000-00005
11. Chedid VG, Kane SV. Bone health in patients with inflammatory bowel diseases. *J Clin Densitom*. 2020;23(2):182-189. doi:10.1016/j.jocd.2019.07.009
12. Bernstein CN, Nugent Z, Shaffer S, Singh H, Marrie RA. Comorbidity before and after a diagnosis of inflammatory bowel disease. *Aliment Pharmacol Ther*. 2021;54(5):637-651. doi:10.1111/apt.16444
13. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. *Inflamm Bowel Dis*. 2018;24(4):916-923. doi:10.1093/ibd/izx089
14. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. *Inflamm Bowel Dis*. 2009;15(2):182-189. doi:10.1002/ibd.20628
15. Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. *Clin Gastroenterol Hepatol*. 2018;16(12):1919-1927.e1913. doi:10.1016/j.cgh.2017.12.052
16. Kaazan P, Li T, Seow W, Bednarz J, Pipicella JL, Krishnaprasad K, et al. Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease. *JGH Open*. 2021;5(9):1063-1070. doi:10.1002/jgh3.12631
17. Kuenzig ME, Stukel TA, Kaplan GG, Murthy SK, Nguyen GC, Talarico R, et al. Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: a population-based cohort study. *J Can Assoc Gastroenterol*. 2021;4(2):e16-e30. doi:10.1093/jcag/gwz048
18. Velissaris D, Pantzaris N, Koniari I, Koutsogiannis N, Karamouzou V, Kotroni I, et al. C-reactive protein and frailty in the elderly: a literature review. *J Clin Med Res*. 2017;9(6):461-465. doi:10.14740/jocmr2959w
19. Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. *Can J Gastroenterol Hepatol*. 2015;29(7):369-372. doi:10.1155/2015/852723
20. Huang X, Xiao M, Jiang B, Wang X, Tang X, Xu X, et al. Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis. *BMC Gastroenterol*. 2022;22(1):534. doi:10.1186/s12876-022-02620-3
21. Kochar B, Cai W, Cagan A, Ananthakrishnan AN. Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2020;52(2):311-318. doi:10.1111/apt.15821
22. Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. Frailty is independently associated with mortality and readmission in hospitalized patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2021;19(10):2054-2063.e2014. doi:10.1016/j.cgh.2020.08.010
23. Kochar B, Jylhävä J, Söderling J, Ritchie CS, Ludvigsson JF, Khalili H, et al. Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study. *Clin Gastroenterol Hepatol*. 2022;20(10):2358-2365.e2311. doi:10.1016/j.cgh.2022.01.001
24. Faye AS, Wen T, Soroush A, Ananthakrishnan AN, Ungaro R, Lawlor G, et al. Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD. *Dig Dis Sci*. 2021;66(12):4178-4190. doi:10.1007/s10620-020-06746-w
25. Kochar B, Cai W, Cagan A, Ananthakrishnan AN. Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases. *Gastroenterology*. 2020;158(8):2104-2111.e2102. doi:10.1053/j.gastro.2020.02.032
26. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf*. 2014;13(1):57-65. doi:10.1517/14740338.2013.827660
27. Wang J, Nakamura TI, Tuskey AG, Behm BW. Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study. *Intest Res*. 2019;17(4):496-503. doi:10.5217/ir.2019.00050
28. Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2015;21(6):1392-1400. doi:10.1097/mib.0000000000000391

29. Drittler D, Schreiber-Stainthorpe W, Delau O, Gurunathan SV, Chodosh J, Segev DL, et al. Severe polypharmacy increases risk of hospitalization among older adults with inflammatory bowel disease. *Am J Gastroenterol*. 2025;120(4):844-855. doi:10.14309/ajg.0000000000003036
30. Asscher VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, Baven-Pronk AMC, van der Marel S, et al. Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2022;20(5):e1006-e1021. doi:10.1016/j.cgh.2021.06.015
31. Mañosa M, Calafat M, de Francisco R, García C, Casanova MJ, Huelín P, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. *Aliment Pharmacol Ther*. 2018;47(5):605-614. doi:10.1111/apt.14494
32. Wisniewski A, Kirchgessner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. *United European Gastroenterol J*. 2020;8(3):303-313. doi:10.1177/2050640619889763
33. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology*. 2011;141(5):1621-1628.e1621-1625. doi:10.1053/j.gastro.2011.06.050
34. Beaugier L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet*. 2009;374(9701):1617-1625. doi:10.1016/s0140-6736(09)61302-7
35. Calafat M, Manosa M, Canete F, Ricart E, Iglesias E, Calvo M, et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. *Aliment Pharmacol Ther*. 2019;50(7):780-788. doi:10.1111/apt.15458
36. de Jong ME, Smits LJT, van Ruyven B, den Broeder N, Russel M, Römkens TEH, et al. Increased discontinuation rates of Anti-TNF therapy in elderly inflammatory bowel disease patients. *J Crohns Colitis*. 2020;14(7):888-895. doi:10.1093/ecco-jcc/jjaa012
37. Porcarì S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, et al. Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian Network for inflammatory bowel diseases (SN-IBD). *Drugs Aging*. 2020;37(5):383-392. doi:10.1007/s40266-020-00744-3
38. Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. *Clin Gastroenterol Hepatol*. 2021;19(5):939-946.e934. doi:10.1016/j.cgh.2020.04.070
39. Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2019;17(9):1736-1743.e1734. doi:10.1016/j.cgh.2018.12.032
40. Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, et al. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. *Aliment Pharmacol Ther*. 2019;49(9):1188-1194. doi:10.1111/apt.15214
41. Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, et al. Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients. *Inflamm Bowel Dis*. 2022;28(5):734-744. doi:10.1093/ibd/izab163
42. Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. *United European Gastroenterol J*. 2020;8(9):1076-1085. doi:10.1177/2050640620951400
43. Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, et al. Safety and efficacy of vedolizumab versus tumor necrosis factor α antagonists in an elderly IBD population: a single institution retrospective experience. *Dig Dis Sci*. 2022;67(7):3129-3137. doi:10.1007/s10620-021-07129-5
44. Dar L, Shani U, Dotan A, Ukashi O, Ben-Horin S, Kopylov U, et al. Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn's disease: a comparative study. *Therap Adv Gastroenterol*. 2024;17:17562848241299752. doi:10.1177/17562848241299752
45. Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C, et al. Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn's disease patients. *Dig Dis Sci*. 2023;68(5):1983-1994. doi:10.1007/s10620-022-07770-8
46. Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. *Aliment Pharmacol Ther*. 2022;56(1):95-109. doi:10.1111/apt.16923
47. Loftus EV, Jr., Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. *Aliment Pharmacol Ther*. 2020;52(8):1353-1365. doi:10.1111/apt.16060
48. Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian real-world study of treatment persistence of ustekinumab in Crohn's disease. *Biologics*. 2021;15:237-245. doi:10.2147/btt.S310076

49. Garg R, Aggarwal M, Mohammed A, Achkar JP, Lashner B, Philpott J, et al. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease. *Indian J Gastroenterol.* 2023;42(5):718-723. doi:10.1007/s12664-023-01391-3
50. Garg R, Aggarwal M, Butler R, Achkar JP, Lashner B, Philpott J, et al. Real-world effectiveness and safety of ustekinumab in elderly Crohn's disease patients. *Dig Dis Sci.* 2022;67(7):3138-3147. doi:10.1007/s10620-021-07117-9
51. Columbel JF, Danese S, Martin N, Kligys K. Safety profile of risankizumab in Crohn's disease patients by age: post-hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. *Gastroenterology.* 2023;164(6):S-1091-S-1092. doi:10.1016/S0016-5085(23)03533-3
52. D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940
53. Lichtenstein GR, Allegretti JR, Loftus EV, Jr., Irving PM, Banerjee R, Charabaty A, et al. Assessment and impact of age on the safety and efficacy of etrasimod in patients with ulcerative colitis: a post hoc analysis of data from the ELEVATE UC clinical program. *Inflamm Bowel Dis.* 2025. doi:10.1093/ibd/izae308
54. Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme. *J Crohns Colitis.* 2024;18(10):1596-1605. doi:10.1093/ecco-jcc/jjae060
55. Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program. *Inflamm Bowel Dis.* 2023;29(1):27-41. doi:10.1093/ibd/izac084
56. Chowla N, Raseen T, Edward L. S29 Safety of upadacitinib in older patients with ulcerative colitis: a real-world experience. *The American College of Gastroenterology.* 118(12S):S8-S9. doi:10.14309/01.ajg.0000995852.39535.01
57. Sandborn WJ, Feagan BG, Loftus EV, Jr., Peyrin-Biroulet L, Van Assche G, D'Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. *Gastroenterology.* 2020;158(8):2123-2138.e2128. doi:10.1053/j.gastro.2020.01.047